The Lancet published peer-reviewed, interim results of the Oxford COVID-19 vaccine (AZD1222) studies find that the vaccine protects against symptomatic disease in 70 percent of cases, with vaccine efficacy (VE) of 62 percent for those given 2 full doses.
Additionally, The Lancet disclosed on December 8, 2020, the VE was reported at 90 percent in those participants given a half, then a full dose (both trial arms pre-specified in the pooled analysis).
Oxford COVID-19 Vaccine Found Adults Protected Against Disease
Large U.S. Claims Study IDs Complications of COVID-19
Association with COVID-19 strong, absolute risk high for viral pneumonia, respiratory failure, acute kidney failure, sepsis
Hep C Testing, Identification Plummet During COVID-19
Reductions seen in hospital-wide and ambulatory clinic HCV testing, identification of new HCV+ patients
Pediatric Appendiceal Perforation Up During COVID-19 Pandemic
Delays in medical care attributable to COVID-19 may cause additional morbidity in children
Masks Containing Metal Could Cause Burns During MRI, FDA Warns
Metal parts include bendable nose clips, staples on the headband, nanoparticles, or antimicrobial coating
FDA Review Finds Pfizer COVID-19 Vaccine Effective After First Dose
Vaccine is expected to receive emergency use authorization later this week
Mystery Illness Strikes Hundreds in India
Symptoms similar to those associated with epilepsy, including headaches, nausea, vomiting, seizures
California Introduces Smartphone Coronavirus Exposure Alert Tool
If a user tests positive for COVID-19, they will receive a code they can use to send an anonymous alert to others
Benefits Confirmed of Adjuvanted Seasonal Influenza Vaccines
A systematic review and meta-analysis presented at the European Scientific Working Group on Influenza virtual conference on December 7, 2020, confirmed the benefit of an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) for adults 65 years and older.
As announced by Seqirus, the results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters.
Benefits Confirmed of Adjuvanted Seasonal Influenza Vaccines
A systematic review and meta-analysis presented at the European Scientific Working Group on Influenza virtual conference on December 7, 2020, confirmed the benefit of an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) for adults 65 years and older.
As announced by Seqirus, the results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters.